Frequently Asked Questions

Middle East Healthcare Company (MEAHCO), the parent company of the Saudi German Health brand in the Kingdom of Saudi Arabia, is one of the region’s leading private healthcare providers. The Company operates a network of hospitals and specialized medical centers across several major cities in the Kingdom, including Jeddah, Riyadh, Hail, Madinah, Makkah, Dammam, and Aseer. Its facilities are designed to function as integrated centers of excellence, delivering comprehensive healthcare services to local communities in accordance with the highest clinical and operational standards.

The Group is also part of the broader Saudi German Health network, which extends across several regional markets, including the United Arab Emirates, Egypt, and Yemen. These affiliations enable the exchange of expertise, knowledge sharing, and collaboration across the network, allowing the Group to leverage regional healthcare capabilities and best practices to further enhance the quality of care and operational excellence.

Middle East Healthcare Company (MEAHCO), the parent company of the Saudi German Health brand in the Kingdom of Saudi Arabia, operates a network of healthcare facilities across several major cities, including Jeddah, Hail, Riyadh, Madinah, Makkah, Dammam, and Aseer. Each facility functions as an integrated center for specialized healthcare services, serving local communities in accordance with the highest clinical, operational, and quality standards.

The Group is also connected through strategic relationships and partnerships within the wider Saudi German Health network across the region. This regional footprint extends to the United Arab Emirates, Egypt, and Yemen, enabling the exchange of expertise, collaboration across healthcare disciplines, and access to a broader network of clinical and operational knowledge that supports the continuous advancement of healthcare services across the Group.

Yes. Middle East Healthcare Company (MEAHCO), the parent company of the Saudi German Health brand in the Kingdom of Saudi Arabia, is a publicly listed company on the Saudi Exchange (Tadawul) and operates in accordance with the applicable regulatory framework under the supervision of the Saudi Capital Market Authority.

The Company is committed to transparent and timely disclosure of material information relevant to investors and shareholders. This includes annual reports, financial statements, Board of Directors disclosures, and General Assembly announcements, which are published through the Saudi Exchange (Tadawul) platform and the Company’s Investor Relations website.

Yes. The Group’s healthcare facilities hold a number of national and international accreditations related to healthcare quality, patient safety, and laboratory standards. These include accreditation from the Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) and the Joint Commission International (JCI), in accordance with the accreditation scope applicable to each facility.

In addition, the Group’s facilities undergo regular internal and external assessments and reviews as part of its ongoing commitment to maintaining high standards of quality, operational excellence, patient safety, and continuous improvement in the healthcare experience and services provided.

Yes. The Group’s healthcare facilities maintain agreements with a number of leading health insurance providers. Coverage generally includes a broad range of medical services, including both outpatient and inpatient care, subject to the terms, conditions, and coverage limits of each insurance provider and policy.

For the most up-to-date list of accepted insurance providers at a specific facility, patients are encouraged to contact the hospital’s Insurance Department or Customer Service team, or visit the Group’s official communication channels for further information.

Appointments can be booked through three main channels:

1. The Saudi German Health mobile application, available on iOS and Android.
2. Our 24/7 contact centre on +966 92 000 7997 inside Saudi Arabia.
3. The Book an Appointment section on our website, with direct links to each hospital.

For urgent and emergency cases, our emergency departments operate around the clock without prior appointment.

Patients can request their medical records, discharge summaries, or formal medical reports through the Medical Records Department at the hospital where treatment was received, or through the patient portal where available.

Requests typically require valid identification, and reports are issued within standard turnaround times set by each facility, in line with confidentiality and data protection regulations.

No. Based on the contents of the published regulatory decision, the matter does not relate to theft, embezzlement, or misappropriation of Company funds. Rather, it concerns accounting treatments and the presentation and recognition of certain revenues and financial claims during previous reporting periods. The published decision did not include any allegations of embezzlement, fraud, or unlawful appropriation of Company assets.

Decisions issued by the Committees for the Resolution of Securities Disputes fall within the scope of regulatory enforcement actions. Such actions typically involve administrative sanctions, including financial penalties and temporary restrictions on working with entities regulated by the Capital Market Authority. These regulatory violations differ in nature and legal consequences from criminal offenses, as they primarily relate to compliance with disclosure requirements, governance obligations, and applicable accounting and reporting standards within the capital market framework.

No. The decision is not related to the Company's current operations or the day-to-day delivery of healthcare services across the Group. It pertains to historical periods and matters that occurred in the past. The Company continues to execute its plans to strengthen corporate governance, internal controls, and compliance frameworks, supporting the ongoing development, stability, and continuity of its operations.

No. The matter is limited to financial, accounting, and governance-related issues and has no impact on the quality of medical care, the continuity of healthcare services, or the rights and welfare of employees. All hospitals within the Group continue to operate as usual, providing healthcare services to patients and beneficiaries without interruption.

One of the Group’s key priorities is strengthening its corporate governance framework and further enhancing its internal control environment. In this regard, the Group launched a comprehensive governance and compliance transformation program in the last quarter of 2024, including the establishment of a dedicated Governance and Compliance Sector. This function is responsible for developing and implementing an integrated Governance, Risk, and Compliance (GRC) framework aligned with leading local and international standards and best practices.

At the same time, the Company continues to strengthen the role of Board committees and enhance its financial controls, governance policies, and compliance procedures to improve accuracy, accountability, regulatory compliance, and the overall effectiveness of its institutional oversight framework.

This ongoing transformation reflects the Group’s commitment to sustainable growth, transparency, and sound corporate governance, while reinforcing the confidence of shareholders and all stakeholders. The Company is managing this development journey through a structured and phased approach, aimed at modernizing its internal control environment and further strengthening its governance, risk management, and compliance capabilities.

No. Based on the information publicly disclosed by the relevant regulatory authorities, the decision relates to regulatory and accounting violations associated with historical reporting periods and the presentation of certain items within the financial statements. The published decision did not include any criminal classification, criminal charges, or criminal characterization of the individuals concerned.

Yes. The decision issued by the Securities Disputes Appeal Committee is final, although the company retains the right to petition for reconsideration. The decision relates to regulatory violations concerning the presentation of revenues in the company's historical financial statements for the period between 2018 and 2021. This clarification is limited to the facts and findings officially established and publicly disclosed by the relevant regulatory authorities.

The Group places the wellbeing, stability, and support of its medical, clinical, and administrative teams among its highest priorities. The Company confirms that the employment status and rights of all employees remain stable and that business operations continue as normal across all facilities. The matter relates to regulatory and accounting issues associated with prior periods and does not affect day-to-day operations, patient care delivery, or employment relationships within the Group.

Management remains proud of the highly skilled professionals who form the foundation of the organization and whose dedication continues to support operational continuity and the delivery of high-quality healthcare services. The Company also believes that its ongoing efforts to strengthen governance, compliance, and internal controls contribute to creating a more stable, transparent, and professional working environment; one that supports its workforce and enhances the overall effectiveness of the institution.

The Group confirms that its operational and commercial activities continue as normal and that it remains committed to fulfilling its contractual and financial obligations in accordance with established practices and agreements. The matter in question relates to accounting treatments associated with prior financial periods and does not directly affect business continuity, day-to-day operations, or the Group’s relationships with suppliers, commercial partners, or financing institutions.

Management also reaffirms its commitment to maintaining and strengthening these strategic partnerships, guided by the principles of transparency, institutional accountability, and mutual trust.

Any material developments or disclosures will be announced in accordance with applicable regulatory requirements and through the Group’s official communication channels, including the Saudi Exchange (Tadawul) platform and the Group’s Investor Relations platform.

The Group remains committed to the principles of transparency and timely disclosure and will continue to keep shareholders and all stakeholders informed of relevant developments in line with its established governance framework, policies, and disclosure procedures.

The Group’s primary message is one of continued commitment to regulatory compliance, sound governance, and transparency. As part of this commitment, the Group has been executing a comprehensive governance, compliance, and internal controls enhancement program since 2024. This initiative includes the strengthening of policies and procedures, the development of institutional oversight frameworks, and the enhancement of the administrative and executive structure in line with the Group’s long-term strategic direction and recognized best practices.

The Group also continues to advance its Governance, Risk, and Compliance (GRC) framework, improve the effectiveness of internal controls and institutional oversight, and strengthen accountability across the organization. These efforts are designed to support the sustainability of the business, safeguard shareholder interests, and reinforce the confidence of all stakeholders.

The decision relates to financial reporting matters during the fiscal years 2018 to 2021, specifically the recognition of certain revenues. It concerns a number of current and former members of the Board of Directors and the Audit Committee.

It is important to note that the decision does not relate to the quality, safety, or continuity of patient care, nor to the Company's clinical operations.

No. Clinical operations, medical and nursing staff, equipment, licensing, and accreditations are fully unaffected. All of our hospitals and facilities continue to operate normally and at full capacity.

Patient safety and clinical excellence remain the Company’s highest and non‑negotiable priority.

Yes. This matter does not have any material impact on the Company’s financial position or its ongoing operations. Patient care services continue uninterrupted, supplier relationships remain unchanged, and all contractual obligations continue to be fulfilled in the ordinary course of business.

The Company’s operations remain supported by a solid financial position and stable cash flows, enabling it to continue delivering healthcare services, meeting its commitments, and executing its strategic priorities as planned.

We have committed to a clear, time bound remediation programme built on five pillars:

1. Reconstituting the Board with reputable, qualified independent members.
2. Appointing a first tier external auditor and commissioning an independent accounting review covering the relevant reporting periods.
3. Adopting a conservative, fully documented revenue recognition policy aligned with international accounting standards.
4. Establishing a dedicated Risk and Disclosure Committee reporting directly to the Board.
5. Publishing a public remediation roadmap with measurable milestones and regular progress reporting.

Shareholders who consider themselves harmed may pursue claims through the formal mechanisms referenced by the Capital Market Authority (CMA).

The Company will facilitate this process transparently and will not obstruct legitimate claims. Our Investor Relations team is available to direct shareholders to the appropriate channels.

All material updates are disclosed on the Saudi Exchange (Tadawul) in line with continuous disclosure requirements, and mirrored on this page.

We have committed to a regular disclosure cadence and will report progress against each remediation milestone as it is delivered.

The Group believes that supporting national development and empowering Saudi talent is a core institutional responsibility and an integral part of its role in advancing the Kingdom’s healthcare sector. As such, the Group continues to invest in attracting, developing, and retaining Saudi professionals across medical, administrative, and technical disciplines, in alignment with the objectives of Saudi Vision 2030 and national workforce development initiatives within the healthcare sector.

The Group’s current Saudization rate stands at approximately 35% of its full-time workforce, increasing to 43% when part-time physicians are included. In addition, the Group continues to support a wide range of training, professional development, residency, and leadership development programs aimed at preparing and empowering Saudi talent, while increasing its representation across specialized, managerial, and leadership positions throughout the organization.

We run structured residency programmes, fellowship pathways, and continuous professional development for Saudi physicians, nurses, technicians, and administrators, many of them accredited by the Saudi Commission for Health Specialties.

In addition, we partner with leading international medical institutions to provide our Saudi staff with exposure to global best practices, hands on clinical training, and leadership development opportunities.